Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Telomir Pharmaceuticals Submits Investigational New Drug Application for Telomir-1 to FDA for Advanced Triple-Negative Breast Cancer
Telomir Pharmaceuticals has taken a significant stride in its mission to combat advanced and metastatic triple-negative breast cancer (TNBC) by…
Read More
Breakthrough in Blue Energy: Lipid-Coated Nanopores Triple Power Density of Osmotic Power Systems
In a significant advancement for renewable energy technology, researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have successfully addressed…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Breakthrough in Osmotic Energy Harvesting EPFL Researchers Utilize Lipid-Coated Nanopores to Triple Blue Energy Efficiency
Researchers at the Ecole Polytechnique Fédérale de Lausanne (EPFL) have announced a significant leap in the field of renewable energy…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
